Lebrikizumab
ApprovedRecruiting 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Atopic Dermatitis
Conditions
Atopic Dermatitis
Trial Timeline
Jun 16, 2025 → Sep 1, 2026
NCT ID
NCT07006792About Lebrikizumab
Lebrikizumab is a approved stage product being developed by Eli Lilly for Atopic Dermatitis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07006792. Target conditions include Atopic Dermatitis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07006792 | Approved | Recruiting |
| NCT05372419 | Phase 3 | Completed |
| NCT05369403 | Phase 3 | Completed |
| NCT04840901 | Phase 1 | Completed |
| NCT04392154 | Phase 3 | Completed |
| NCT04250350 | Phase 3 | Completed |
| NCT04250337 | Phase 3 | Completed |
| NCT04178967 | Phase 3 | Completed |
| NCT04146363 | Phase 3 | Completed |
Competing Products
20 competing products in Atopic Dermatitis